First trimester diagnosis and screening for fetal aneuploidy

Genetics in Medicine

Volumn 10, Issue 1, 2008, Pages 73-75

  Driscoll, Deborah A ^a   Gross, Susan J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aneuploidy; Multiple marker screening; Nuchal translucency

Indexed keywords

BIOLOGICAL MARKER;

AMERICAN COLLEGE OF MEDICAL GENETICS; ANEUPLOIDY; CHORION VILLUS SAMPLING; DOWN SYNDROME; FETAL ANEUPLOIDY; FIRST TRIMESTER PREGNANCY; HEART DISEASE; MEDICAL SOCIETY; NEURAL TUBE DEFECT; PRACTICE GUIDELINE; PRENATAL SCREENING; REVIEW; SECOND TRIMESTER PREGNANCY; TRISOMY 18; ULTRASOUND;

ANEUPLOIDY; DOWN SYNDROME; FEMALE; FETUS; GENETIC MARKERS; GENETIC SCREENING; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 38149059050     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31815efde8     Document Type: Review

References (16)

1. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109:217-227.
2. Malone FD, Canick JA, Ball RH, Nyberg DA, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-2011.
3. Spencer K, Souter V, Tul N, Snijders R, et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-237.
4. Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. BJOG 2004;111:521-531.
5. Caughey AB, Hopkins LM, Norton ME. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 2006;108:612-616.
6. Scott F, Peters H, Boogert T, Robertson R, et al. The loss rates for invasive prenatal testing in a specialised obstetric ultrasound practice. Aust NZJ Obstet Gynecol 2002;42:55-58.
7. Eddleman KA, Malone FD, Sullivan L, Dukes K, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006;108:1067-1072.
8. Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev. 2003;(3):CD003252.
9. Spencer K. Aneuploidy screening in the first trimester. Am J Med Genet C Semin Med Genet 2007;145:18-32.
10. Sonek J. First trimester ultrasonography in screening and detection of fetal anomalies. Am J Med Genet C Semin Med Genet 2007;145:45-61.
11. Cicero S, Avgidou K, Rembouskos G, Kagan KO, et al. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006;195:109-114.
12. Makrydimas G, Sotiriadis A, Huggon IC, Simpson J, et al. Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers. Am J Obstet Gynecol 2005;192(1):89 -95.
13. Wapner R, Thom E, Simpson JL, Pergament E, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-1413.
14. Sharma G, McCullough LB, Chervenak FA. Ethical considerations of early (first vs. second trimester) risk assessment disclosure for trisomy 21 and patient choice in screening versus diagnostic testing. Am J Med Genet C Semin Med Genet 2007;145:99-104.
15. Platt LD, Greene N, Johnson A, Zachary J, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004;104:661-666.
16. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005;25:645-652.